血液悪性腫瘍検出の世界市場レポート 2025年

血液悪性腫瘍検出の市場規模は今後数年で急成長が見込まれます。2029年には年間平均成長率（CAGR）15.2%で54億6,000万米ドルに成長します。予測期間の成長は、ヘルスケアインフラの拡大、政府のイニシアティブと資金調達、医療保険の適用範囲拡大、データ管理システムの改善に起因しています。予測期間における主な動向としては、遺伝子およびエピジェネティックデータの解像度の向上、タンパク質発現のプロファイリング技術の高度化、免疫測定技術の強化、ナノ材料およびナノセンサーの開発、遠隔医療プラットフォームの拡大などが挙げられます。

血液がんの罹患率の上昇は、血液悪性腫瘍検出市場の成長を促進すると予想されています。血液がんには、血液、骨髄、リンパ系に影響を及ぼすがんが含まれ、正常な血球の生産と機能を障害します。血液がんの有病率増加の要因としては、人口の高齢化や、より早期かつ正確な検出を可能にする診断技術の進歩が挙げられます。血液悪性腫瘍の効果的な発見は、早期かつ正確な診断を可能にし、個別化された効果的な治療戦略を促進するため、治療にとって極めて重要です。例えば、米国を拠点とする専門機関である白血病リンパ腫協会は、2024年3月に、米国では約43万7,337人が白血病を患っているか寛解状態にあり、2024年には約5万9,610人が新たに診断される見込みであると報告しています。その結果、血液がんの有病率の増加が血液悪性腫瘍検出市場の拡大に拍車をかけています。

血液悪性腫瘍検出市場の主要企業は、診断精度と患者の転帰を改善するため、血液がん診断検査などの先進ソリューションの開発に注力しています。これらの検査は、白血病、リンパ腫、多発性骨髄腫などの血液悪性腫瘍の検出と確認に不可欠です。例えば、2023年11月、米国の研究・治療施設であるロズウェル・パーク総合がんセンターは、次世代遺伝子シーケンス技術を活用した最先端の血液がん診断検査であるPanHemeを発表しました。PanHemeは72時間以内に血液がんの遺伝子変異を同定するもので、従来の方法より大幅に改善されています。この迅速な対応により、個別化された治療計画の開発や、特定の変異に基づくFDA認可の標的療法の使用が可能になります。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、新型コロナウイルス感染症、そして景気回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界血液悪性腫瘍検出 PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の血液悪性腫瘍検出市場：成長率分析
• 世界の血液悪性腫瘍検出市場の実績：規模と成長, 2019-2024
• 世界の血液悪性腫瘍検出市場の予測：規模と成長, 2024-2029, 2034F
• 世界血液悪性腫瘍検出総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の血液悪性腫瘍検出市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• ポリメラーゼ連鎖反応
• 免疫化学
• 次世代シーケンシング
• 蛍光in situハイブリダイゼーション
• その他のタイプ
• 世界の血液悪性腫瘍検出市場：用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 多発性骨髄腫
• 骨髄異形成症候群
• 白血病
• 骨髄増殖性腫瘍
• リンパ腫
• その他の用途
• 世界の血液悪性腫瘍検出市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• 専門クリニック
• ホームケア
• その他のエンドユーザー
• 世界の血液悪性腫瘍検出市場ポリメラーゼ連鎖反応のサブセグメンテーション（タイプ別）、実績と予測, 2019-2024, 2024-2029F, 2034F
• リアルタイムPCR（qPCR）
• デジタルPCR
• 逆転写PCR（RT-PCR）
• ネストPCR
• マルチプレックスPCR
• PCRベースの検出キット
• 世界の血液悪性腫瘍検出市場免疫化学のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 酵素免疫測定（ELISA）
• 免疫組織化学（IHC）
• ウェスタンブロッティング
• フローサイトメトリー
• 免疫蛍光法
• 免疫組織化学染色キット
• 世界の血液悪性腫瘍検出市場次世代シーケンシングの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 全ゲノムシークエンシング（WGS）
• 全エクソームシーケンシング（WES）
• ターゲットシーケンシング
• RNAシーケンシング（RNA-Seq）
• 液体生検NGS
• 造血悪性腫瘍のための次世代シーケンシングキット
• 世界の血液悪性腫瘍検出市場、蛍光in situハイブリダイゼーションのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 染色体特異的FISHプローブ
• DNAフィッシュ
• RNAフィッシュ
• マルチカラーの魚
• 白血病およびリンパ腫のFISH法による検出キット
• 世界の血液悪性腫瘍検出市場、その他のタイプのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 細胞遺伝学的検査
• サイトメトリーベースの検出
• 磁気共鳴画像（MRI）による検出
• 高速液体クロマトグラフィー（HPLC）
• 血液悪性腫瘍検出の質量分析

第7章 地域別・国別分析

• 世界の血液悪性腫瘍検出市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の血液悪性腫瘍検出市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 血液悪性腫瘍検出市場：競合情勢
• 血液悪性腫瘍検出市場：企業プロファイル
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Sanofi-Aventis U.S LLC Overview, Products and Services, Strategy and Financial Analysis
  • Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Abbott Laboratories Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Novartis AG
• Becton Dickinson and Company
• Laboratory Corporation of America Holdings
• ICON plc
• Agilent Technologies Inc.
• Illumina Inc.
• Beckman Coulter Inc.
• Sysmex Corporation
• Bio-Rad Laboratories Inc.
• QIAGEN N.V.
• Kite Pharma Inc.
• ArcherDx Inc.
• Invitae Corporation
• NeoGenomics Laboratories Inc.
• Tempus Labs Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 血液悪性腫瘍検出市場2029：新たな機会を提供する国
• 血液悪性腫瘍検出市場2029：新たな機会を提供するセグメント
• 血液悪性腫瘍検出市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Hematologic malignancy detection involves identifying cancers that impact the blood, bone marrow, and lymphatic system, such as leukemia, lymphoma, and multiple myeloma. These types of cancers interfere with the normal production and function of blood cells.

Key methods for detecting hematologic malignancies include polymerase chain reaction (PCR), immunochemistry, next-generation sequencing, fluorescence in situ hybridization, and other techniques. PCR is a method used to amplify small DNA samples, which facilitates the analysis and detection of genetic mutations or abnormalities linked to hematologic cancers. This technique is applicable for conditions like multiple myeloma, myelodysplastic syndrome, leukemia, myeloproliferative neoplasms, and lymphoma, and is used in various settings, including hospitals, specialty clinics, and home care.

The hematologic malignancies detection market research report is one of a series of new reports from The Business Research Company that provides hematologic malignancies detection market statistics, including hematologic malignancies detection industry global market size, regional shares, competitors with a hematologic malignancies detection market share, detailed hematologic malignancies detection market segments, market trends and opportunities, and any further data you may need to thrive in the hematologic malignancies detection industry. This hematologic malignancies detection market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The hematologic malignancies detection market size has grown rapidly in recent years. It will grow from $2.68 $ billion in 2024 to $3.1 $ billion in 2025 at a compound annual growth rate (CAGR) of 15.6%. The growth in the historic period can be attributed to rising incidence rates of conditions, increased awareness about their importance, increased demand from both patients, supportive regulatory frameworks, and the rise of digital health technology.

The hematologic malignancies detection market size is expected to see rapid growth in the next few years. It will grow to $5.46 $ billion in 2029 at a compound annual growth rate (CAGR) of 15.2%. The growth in the forecast period can be attributed to expanding healthcare infrastructure, government initiatives and funding, the expansion of health insurance coverage, and improvements in data management systems. Major trends in the forecast period include enhanced resolution of genetic and epigenetic data, advanced techniques for profiling protein expressions, enhanced immunoassay techniques, the development of nanomaterials and nano sensors, and the expansion of telemedicine platforms.

The rising incidence of blood cancer is anticipated to drive the growth of the hematologic malignancy detection market. Blood cancer, which includes cancers affecting the blood, bone marrow, or lymphatic system, disrupts normal blood cell production and function. Factors contributing to the increased prevalence of blood cancer include aging populations and advancements in diagnostic techniques that enable earlier and more precise detection. Effective detection of hematologic malignancies is crucial for treatment, as it allows for early and accurate diagnosis, facilitating personalized and effective treatment strategies. For example, in March 2024, the Leukemia & Lymphoma Society, a US-based professional organization, reported that approximately 437,337 people in the US are living with or in remission from leukemia, with around 59,610 new cases expected to be diagnosed in 2024. Consequently, the growing prevalence of blood cancer is fueling the expansion of the hematologic malignancy detection market.

Leading companies in the hematologic malignancy detection market are concentrating on developing advanced solutions, such as blood cancer diagnostic tests, to improve diagnostic accuracy and patient outcomes. These tests are essential for detecting and confirming the presence of hematologic malignancies like leukemia, lymphoma, and multiple myeloma. For instance, in November 2023, Roswell Park Comprehensive Cancer Center, a US-based research and treatment facility, introduced PanHeme, a cutting-edge blood cancer diagnostic test that leverages next-generation gene sequencing technology. PanHeme identifies genetic mutations in blood cancers within 72 hours, a significant improvement over traditional methods. This rapid turnaround allows for the development of personalized treatment plans and the use of targeted FDA-approved therapies based on specific mutations.

In February 2022, Becton, Dickinson and Company, a US-based medical technology firm, acquired Cytognos S.L. for an undisclosed amount. This acquisition allows Becton, Dickinson and Company to enhance its capabilities in blood cancer diagnostics and post-treatment monitoring by leveraging Cytognos' expertise in flow cytometry and minimal residual disease detection. Cytognos S.L., based in Spain, specializes in clinical diagnostics, particularly in immune monitoring and blood cancer diagnosis solutions.

Major companies operating in the hematologic malignancies detection market are AbbVie Inc., Sanofi-Aventis U.S LLC, Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc., Abbott Laboratories Inc., Novartis AG, Becton Dickinson and Company, Laboratory Corporation of America Holdings, ICON plc, Agilent Technologies Inc., Illumina Inc., Beckman Coulter Inc., Sysmex Corporation, Bio-Rad Laboratories Inc., QIAGEN N.V., Kite Pharma Inc., ArcherDx Inc., Invitae Corporation, NeoGenomics Laboratories Inc., Tempus Labs Inc., Adaptive Biotechnologies Corporation, Freenome Inc., Invivoscribe Technologies Inc., Asuragen Inc., Celldex Therapeutics Inc.

North America was the largest region in the hematologic malignancies detection market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hematologic malignancies detection market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the hematologic malignancies detection market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The hematologic malignancy detection market consists of revenues earned by entities by providing services such as diagnostic testing, imaging studies, clinical evaluation, genetic counseling, and monitoring and follow-up. The market value includes the value of related goods sold by the service provider or included within the service offering. The hematologic malignancy detection market also includes sales of products including bone marrow aspiration and biopsy kits, flow cytometers, fluorescence in situ hybridization (FISH), and IHC staining kits. Values in this market are factory gate values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Hematologic Malignancies Detection Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on hematologic malignancies detection market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for hematologic malignancies detection ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The hematologic malignancies detection market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Polymerase Chain Reaction; Immunochemistry; Next Generation Sequencing; Fluorescence In Situ Hybridization; Other Types
• 2) By Application: Multiple Myeloma; Myelodysplastic Syndrome; Leukemia; Myeloproliferative Neoplasms; Lymphoma; Other Application
• 3) By End-Users: Hospitals; Specialty Clinics; Homecare; Other End-Users
• Subsegments:
• 1) By Polymerase Chain Reaction (PCR): Real-Time PCR (qPCR); Digital PCR; Reverse Transcription PCR (RT-PCR); Nested PCR; Multiplex PCR; PCR-Based Detection Kits
• 2) By Immunochemistry: Enzyme-Linked Immunosorbent Assay (ELISA); Immunohistochemistry (IHC); Western Blotting; Flow Cytometry; Immunofluorescence; Immunohistochemical Staining Kits
• 3) By Next Generation Sequencing (NGS): Whole Genome Sequencing (WGS); Whole Exome Sequencing (WES); Targeted Sequencing; RNA Sequencing (RNA-Seq); Liquid Biopsy NGS; Next-Generation Sequencing Kits For Hematologic Malignancies
• 4) By Fluorescence In Situ Hybridization (FISH): Chromosome-Specific FISH Probes; DNA FISH; RNA FISH; Multicolor FISH; FISH-Based Detection Kits For Leukemia And Lymphoma
• 5) By Other Types: Cytogenetic Testing; Cytometry-Based Detection; Magnetic Resonance Imaging (MRI) For Detection; High-Performance Liquid Chromatography (HPLC); Mass Spectrometry For Hematologic Malignancies Detection
• Companies Mentioned: AbbVie Inc.; Sanofi-Aventis U.S LLC; Bristol-Myers Squibb Company; Thermo Fisher Scientific Inc.; Abbott Laboratories Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Hematologic Malignancies Detection Market Characteristics

3. Hematologic Malignancies Detection Market Trends And Strategies

4. Hematologic Malignancies Detection Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Hematologic Malignancies Detection Growth Analysis And Strategic Analysis Framework

• 5.1. Global Hematologic Malignancies Detection PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Hematologic Malignancies Detection Market Growth Rate Analysis
• 5.4. Global Hematologic Malignancies Detection Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Hematologic Malignancies Detection Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Hematologic Malignancies Detection Total Addressable Market (TAM)

6. Hematologic Malignancies Detection Market Segmentation

• 6.1. Global Hematologic Malignancies Detection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Polymerase Chain Reaction
• Immunochemistry
• Next Generation Sequencing
• Fluorescence In Situ Hybridization
• Other Types
• 6.2. Global Hematologic Malignancies Detection Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Multiple Myeloma
• Myelodysplastic Syndrome
• Leukemia
• Myeloproliferative Neoplasms
• Lymphoma
• Other Applications
• 6.3. Global Hematologic Malignancies Detection Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Specialty Clinics
• Homecare
• Other End-Users
• 6.4. Global Hematologic Malignancies Detection Market, Sub-Segmentation Of Polymerase Chain Reaction, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Real-Time PCR (qPCR)
• Digital PCR
• Reverse Transcription PCR (RT-PCR)
• Nested PCR
• Multiplex PCR
• PCR-Based Detection Kits
• 6.5. Global Hematologic Malignancies Detection Market, Sub-Segmentation Of Immunochemistry, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Enzyme-Linked Immunosorbent Assay (ELISA)
• Immunohistochemistry (IHC)
• Western Blotting
• Flow Cytometry
• Immunofluorescence
• Immunohistochemical Staining Kits
• 6.6. Global Hematologic Malignancies Detection Market, Sub-Segmentation Of Next Generation Sequencing, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Whole Genome Sequencing (WGS)
• Whole Exome Sequencing (WES)
• Targeted Sequencing
• RNA Sequencing (RNA-Seq)
• Liquid Biopsy NGS
• Next-Generation Sequencing Kits For Hematologic Malignancies
• 6.7. Global Hematologic Malignancies Detection Market, Sub-Segmentation Of Fluorescence In Situ Hybridization, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Chromosome-Specific FISH Probes
• DNA FISH
• RNA FISH
• Multicolor FISH
• FISH-Based Detection Kits For Leukemia And Lymphoma
• 6.8. Global Hematologic Malignancies Detection Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Cytogenetic Testing
• Cytometry-Based Detection
• Magnetic Resonance Imaging (MRI) For Detection
• High-Performance Liquid Chromatography (HPLC)
• Mass Spectrometry For Hematologic Malignancies Detection

7. Hematologic Malignancies Detection Market Regional And Country Analysis

• 7.1. Global Hematologic Malignancies Detection Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Hematologic Malignancies Detection Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Hematologic Malignancies Detection Market

• 8.1. Asia-Pacific Hematologic Malignancies Detection Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Hematologic Malignancies Detection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Hematologic Malignancies Detection Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Hematologic Malignancies Detection Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Hematologic Malignancies Detection Market

• 9.1. China Hematologic Malignancies Detection Market Overview
• 9.2. China Hematologic Malignancies Detection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Hematologic Malignancies Detection Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Hematologic Malignancies Detection Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Hematologic Malignancies Detection Market

• 10.1. India Hematologic Malignancies Detection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Hematologic Malignancies Detection Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Hematologic Malignancies Detection Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Hematologic Malignancies Detection Market

• 11.1. Japan Hematologic Malignancies Detection Market Overview
• 11.2. Japan Hematologic Malignancies Detection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Hematologic Malignancies Detection Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Hematologic Malignancies Detection Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Hematologic Malignancies Detection Market

• 12.1. Australia Hematologic Malignancies Detection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Hematologic Malignancies Detection Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Hematologic Malignancies Detection Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Hematologic Malignancies Detection Market

• 13.1. Indonesia Hematologic Malignancies Detection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Hematologic Malignancies Detection Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Hematologic Malignancies Detection Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Hematologic Malignancies Detection Market

• 14.1. South Korea Hematologic Malignancies Detection Market Overview
• 14.2. South Korea Hematologic Malignancies Detection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Hematologic Malignancies Detection Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Hematologic Malignancies Detection Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Hematologic Malignancies Detection Market

• 15.1. Western Europe Hematologic Malignancies Detection Market Overview
• 15.2. Western Europe Hematologic Malignancies Detection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Hematologic Malignancies Detection Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Hematologic Malignancies Detection Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Hematologic Malignancies Detection Market

• 16.1. UK Hematologic Malignancies Detection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Hematologic Malignancies Detection Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Hematologic Malignancies Detection Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Hematologic Malignancies Detection Market

• 17.1. Germany Hematologic Malignancies Detection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Hematologic Malignancies Detection Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Hematologic Malignancies Detection Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Hematologic Malignancies Detection Market

• 18.1. France Hematologic Malignancies Detection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Hematologic Malignancies Detection Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Hematologic Malignancies Detection Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Hematologic Malignancies Detection Market

• 19.1. Italy Hematologic Malignancies Detection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Hematologic Malignancies Detection Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Hematologic Malignancies Detection Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Hematologic Malignancies Detection Market

• 20.1. Spain Hematologic Malignancies Detection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Hematologic Malignancies Detection Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Hematologic Malignancies Detection Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Hematologic Malignancies Detection Market

• 21.1. Eastern Europe Hematologic Malignancies Detection Market Overview
• 21.2. Eastern Europe Hematologic Malignancies Detection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Hematologic Malignancies Detection Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Hematologic Malignancies Detection Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Hematologic Malignancies Detection Market

• 22.1. Russia Hematologic Malignancies Detection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Hematologic Malignancies Detection Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Hematologic Malignancies Detection Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Hematologic Malignancies Detection Market

• 23.1. North America Hematologic Malignancies Detection Market Overview
• 23.2. North America Hematologic Malignancies Detection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Hematologic Malignancies Detection Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Hematologic Malignancies Detection Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Hematologic Malignancies Detection Market

• 24.1. USA Hematologic Malignancies Detection Market Overview
• 24.2. USA Hematologic Malignancies Detection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Hematologic Malignancies Detection Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Hematologic Malignancies Detection Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Hematologic Malignancies Detection Market

• 25.1. Canada Hematologic Malignancies Detection Market Overview
• 25.2. Canada Hematologic Malignancies Detection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Hematologic Malignancies Detection Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Hematologic Malignancies Detection Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Hematologic Malignancies Detection Market

• 26.1. South America Hematologic Malignancies Detection Market Overview
• 26.2. South America Hematologic Malignancies Detection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Hematologic Malignancies Detection Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Hematologic Malignancies Detection Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Hematologic Malignancies Detection Market

• 27.1. Brazil Hematologic Malignancies Detection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Hematologic Malignancies Detection Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Hematologic Malignancies Detection Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Hematologic Malignancies Detection Market

• 28.1. Middle East Hematologic Malignancies Detection Market Overview
• 28.2. Middle East Hematologic Malignancies Detection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Hematologic Malignancies Detection Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Hematologic Malignancies Detection Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Hematologic Malignancies Detection Market

• 29.1. Africa Hematologic Malignancies Detection Market Overview
• 29.2. Africa Hematologic Malignancies Detection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Hematologic Malignancies Detection Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Hematologic Malignancies Detection Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Hematologic Malignancies Detection Market Competitive Landscape And Company Profiles

• 30.1. Hematologic Malignancies Detection Market Competitive Landscape
• 30.2. Hematologic Malignancies Detection Market Company Profiles
  • 30.2.1. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Sanofi-Aventis U.S LLC Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Abbott Laboratories Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Hematologic Malignancies Detection Market Other Major And Innovative Companies

• 31.1. Novartis AG
• 31.2. Becton Dickinson and Company
• 31.3. Laboratory Corporation of America Holdings
• 31.4. ICON plc
• 31.5. Agilent Technologies Inc.
• 31.6. Illumina Inc.
• 31.7. Beckman Coulter Inc.
• 31.8. Sysmex Corporation
• 31.9. Bio-Rad Laboratories Inc.
• 31.10. QIAGEN N.V.
• 31.11. Kite Pharma Inc.
• 31.12. ArcherDx Inc.
• 31.13. Invitae Corporation
• 31.14. NeoGenomics Laboratories Inc.
• 31.15. Tempus Labs Inc.

32. Global Hematologic Malignancies Detection Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Hematologic Malignancies Detection Market

34. Recent Developments In The Hematologic Malignancies Detection Market

35. Hematologic Malignancies Detection Market High Potential Countries, Segments and Strategies

• 35.1 Hematologic Malignancies Detection Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Hematologic Malignancies Detection Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Hematologic Malignancies Detection Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer